scholarly journals Applications of the capillary electrophoresis in the development process and quality control of the monoclonal antibody for clinical use.

2008 ◽  
Vol 52 (3) ◽  
pp. 139-144
Author(s):  
Etsuo Arai
Keyword(s):  
Monoclonal Antibody ◽  
Quality Control ◽  
Capillary Electrophoresis ◽  
Development Process ◽  
Clinical Use

An enzyme-linked immunoassay using anti-miroestrol monoclonal antibody for quality control of Pueraria candollei products

Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
T Kitisripanya ◽  
J Komaikul ◽  
K Jutathis ◽  
O Udomsin ◽  
H Tanaka ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Quality Control ◽  
Pueraria Candollei

HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control

2018 ◽  
Vol 149 ◽  
pp. 214-224 ◽  
Author(s):  
Michal Douša ◽  
Markéta Slavíková ◽  
Tomáš Kubelka ◽  
Josef Černý ◽  
Petr Gibala ◽  
...  
Keyword(s):  
Quality Control ◽  
Development Process ◽  
Obeticholic Acid ◽  
Related Compounds

Capillary Electrophoresis for the Quality Control of Intact Therapeutic Monoclonal Antibodies

2017 ◽  
pp. 305-361 ◽  
Author(s):  
Anne-Lise Marie ◽  
Grégory Rouby ◽  
Emmanuel Jaccoulet ◽  
Claire Smadja ◽  
Nguyet Thuy Tran ◽  
...  
Keyword(s):  
Quality Control ◽  
Capillary Electrophoresis ◽  
Monoclonal Antibodies ◽  
Therapeutic Monoclonal Antibodies

scholarly journals Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review

2020 ◽  
Vol 10 (3) ◽  
pp. 79 ◽  
Author(s):  
Apostolos Papachristos ◽  
Gregory B. Sivolapenko
Keyword(s):  
Colorectal Cancer ◽  
Lung Cancer ◽  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Therapeutic Drug ◽  
Clinical Use ◽  
Treatment Optimization ◽  
Patients With Cancer ◽  
Research Fields ◽  
Bevacizumab Treatment

Bevacizumab is a monoclonal antibody that targets VEGF-A and inhibits tumor angiogenesis. Bevacizumab is approved for the treatment of various cancer, including metastatic colorectal cancer (mCRC), ovarian cancer, lung cancer, and others. Thus, it is widely used in oncology, but contrary to other therapeutic classes, there is still a lack of validating predictive factors for treatment outcomes with these agents. In recent years, the research for factors predictive of anti-VEGF treatments and especially bevacizumab response has been one of the most competitive translational research fields. Herein, we review and present the available literature of the clinical use of biomarkers, pharmacogenomics (PG), and therapeutic drug monitoring (TDM) approaches that can be used for the optimization of bevacizumab use in the era of precision medicine.

Sign in / Sign up

Export Citation Format

Share Document